Table 5: Summary of antiretroviral regimen recommendations for patients who require concomitant HIV and hepatitis C treatment.

RecommendedAlternativeNot recommended

Sofosbuvir 400 mg/ledipasvir 90 mg once dailyNo restrictions with first or second line ART regimensIn patients with preexisting renal dysfunction or significant risk factors for nephrotoxicity: may wish to avoid tenofovir-containing regimens due to potential for ↑ tenofovir concentrations

Paritaprevir 150 mg/ritonavir 100 mg/ombitasvir 25 mg once daily + dasabuvir 250 mg BID with foodAtazanavir (without additional ritonavir), raltegravir, and DolutegravirDarunavir (without additional ritonavir)Ritonavir- or cobicistat-boosted regimens; efavirenz, etravirine, and rilpivirine

150 mg daily plus sofosbuvir 400 mg daily with food
Dolutegravir, raltegravir, or rilpivirine-based regimensRitonavir- or cobicistat-boosted regimens; efavirenz, etravirine, and nevirapine

Daclatasvir 60 mg daily plus sofosbuvir 400 mg dailyAtazanavir (requires decrease in daclatasvir dose to 30 mg daily), darunavir, dolutegravir, raltegravir, or rilpivirine-based regimensEfavirenz (requires increase in daclatasvir dose to 90 mg daily)Etravirine and nevirapine

BID: twice daily.